Cleveland Clinic Florida

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Recruiting

  Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis

  NCT04990128· Phase 3· The Cleveland Clinic· Source

• Recruiting

  A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

  NCT07214376· Pulnovo Medical, Inc.· Source

• Active, not recruiting

  ColoSeal™ ICD System Anastomotic Protection Pivotal Study

  NCT07429110· Averto Medical, Inc.· Source

• Recruiting

  Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

  NCT07222657· Phase 2· Case Comprehensive Cancer Center· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Recruiting

  Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

  NCT07211178· Tempus AI· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  IVUS CHIP UPP Registry

  NCT06625801· ECRI bv· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Rapamycin Holdings Inc.· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

  NCT06793371· Phase 2· Cytokinetics· Source

• Recruiting

  Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

  NCT06526195· Abbott Medical Devices· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

  NCT06637501· Phase 2· BeOne Medicines· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

  NCT06402968· Zeenat Qureshi Stroke Institute· Source

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

• Recruiting

  Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

  NCT05677100· Procyrion· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Recruiting

  A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05552222· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

  NCT05451810· Phase 2· Genmab· Source

• Recruiting

  Global Cardio Oncology Registry

  NCT05598879· The Cleveland Clinic· Source

• Recruiting

  Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

  NCT05185492· STAVROS G DRAKOS· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Mirum Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Recruiting

  Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

  NCT04669548· Potrero Medical· Source

• Active, not recruiting

  Abemaciclib and Letrozole to Treat Endometrial Cancer

  NCT04393285· Phase 2· Gynecologic Oncology Group· Source

• Recruiting

  Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

  NCT04427384· GT Medical Technologies, Inc.· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· United Therapeutics· Source

• Recruiting

  GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

  NCT03821129· W.L.Gore & Associates· Source

• Recruiting

  Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

  NCT03659448· Phase 3· Surgimab· Source

• Active, not recruiting

  A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

  NCT03539744· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  AMPLATZER PFO Occluder Post Approval Study

  NCT03309332· Abbott Medical Devices· Source

Showing 50 of 58.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure5 recruiting
• High blood pressure5 recruiting
• Amyloidosis3 recruiting
• Coronary artery disease3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Crohn's disease2 recruiting
• Multiple myeloma2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bronchiectasis1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Meningioma1 recruiting
• Metastatic breast cancer1 recruiting
• Myocarditis1 recruiting
• Osteoarthritis1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

  NCT05776225· United Therapeutics· Source

• Terminated

  BAriatric Surgery Induced Chromosomal Change

  NCT05903521· The Cleveland Clinic· Source

• Terminated

  A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

  NCT05814016· Phase 2· Takeda· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

  NCT05363280· Phase 2· Advenchen Pharmaceuticals, LLC.· Source

• Recruiting

  Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

  NCT05168163· Phase 2· Academic and Community Cancer Research United· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Bayer· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

  NCT04825288· Phase 1/2· XBiotech, Inc.· Source

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Phase 2· Gossamer Bio USA, Inc.· Source

• Completed

  Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

  NCT04260126· Phase 2· PDS Biotechnology Corp.· Source

• Terminated

  CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

  NCT04698187· Phase 2· Regeneron Pharmaceuticals· Source

• Withdrawn

  Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients

  NCT04170335· The Cleveland Clinic· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

  NCT04578392· The Cleveland Clinic· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

  NCT04075825· Phase 3· Takeda· Source

• Completed

  Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

  NCT04075526· Phase 1· NYU Langone Health· Source

• Completed

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

  NCT03362177· Phase 3· Amgen· Source

• Completed

  A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

  NCT03901963· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

  NCT03737149· Zimmer Biomet· Source

• Completed

  HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients

  NCT03500315· Johns Hopkins University· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  Vasopressin in Intraabdominal Pressure Elevation

  NCT03707054· The Cleveland Clinic· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Terminated

  Connect® MM- The Multiple Myeloma Disease Registry

  NCT01081028· Celgene· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Trigeminal neuralgia15 works · 0 trials